Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes
Selçuk Adabağ, Jane Chen
Abstract
To the Editor: Kirchhof et al. (Sept. 28 issue)(1) found that anticoagulation with edoxaban did not reduce the incidence of cardiovascular death, stroke, or systemic embolism as compared with placebo among patients with atrial high-rate episodes (AHREs) detected by implantable devices. In the NOAH-AFNET 6 trial, the incidence of stroke, despite a median CHA(2)DS(2)-VASc score of 4 (on a scale from 0 to 9, with higher scores indicating a greater risk of stroke), was approximately 1% per patient-year. Among patients with atrial fibrillation, anticoagulation is recommended in those who have a minimum of two risk factors for stroke, specifically those . . .
Topics & Concepts
MedicineEdoxabanAtrial fibrillationIntensive care medicineVenous thromboembolismCardiologyInternal medicineWarfarinThrombosisRivaroxabanAtrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsCardiac electrophysiology and arrhythmias